Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer (DeeP-C)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Exact Sciences Corporation
ClinicalTrials.gov Identifier:
NCT01397747
First received: July 18, 2011
Last updated: June 18, 2013
Last verified: June 2013

July 18, 2011
June 18, 2013
June 2011
February 2013   (final data collection date for primary outcome measure)
Sensitivity and Specificity of the Exact CRC screening test with comparison to colonoscopy, both with respect to cancer. [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
An optical colonoscopic procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination.
Sensitivity and Specificity of the Exact CRC screening test with comparison to colonoscopy, both with respect to cancer and advanced adenoma. [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
An optical colonoscopic procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination.
Complete list of historical versions of study NCT01397747 on ClinicalTrials.gov Archive Site
To compare the performance of the Exact CRC screening test to a commercially available FIT, both with respect to cancer and advanced adenoma. [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
Lesions will be confirmed as a malignant or precancerous by colonoscopy and histopathologic examination.
Same as current
Not Provided
Not Provided
 
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer: DeeP-C Study

The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination.

The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

Patients who are at average risk of developing colorectal cancer who are eligible for colorectal cancer screening will be asked to collect a single stool sample for the Exact CRC screening test and for the commercially available FIT assay. Subjects will undergo colonoscopy within 90 days of enrollment. Representative histopathology slides from tissue biopsied or excised during colonoscopy and representative histopathology slides resulting from subsequent definitive surgery may be retrieved in order to be evaluated by central pathology to confirm diagnosis and staging.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Residual stool samples may be archived for further research. Clinical data and samples will be kept in a manner that preserves anonymity of the subjects, using the subject ID as the only tracking information. Specimens will be stored in a commercial biorepository contracted by Exact Sciences or at Exact Sciences and may be used for future research.

Non-Probability Sample

Patients at average risk of developing colorectal cancer.

  • Colorectal Neoplasms
  • Digestive System Diseases
  • Colonic Diseases
  • Colorectal Cancer
Not Provided
Average risk patients
Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12776
May 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject is average risk for development of colorectal cancer (as defined by the inclusion and exclusion criteria below).
  2. Subject is able and willing to undergo a screening colonoscopy within 90 days of enrollment.
  3. Subject is 50 to 84 years of age inclusive.
  4. Subject is able to comprehend, sign, and date the written informed consent document to participate in the study.
  5. Subject is able and willing to provide stool samples according to written instructions provided to them.

Exclusion Criteria:

  1. Subject has any condition which, in the opinion of the investigator should preclude participation in the study.
  2. Subject has undergone colonoscopy within the previous nine (9) years.
  3. Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous five (5) years.
  4. Subject has a history of colorectal cancer or adenoma.
  5. Subject has a history of aerodigestive tract cancer.
  6. Subject has had a positive fecal occult blood test or FIT within the previous six (6) months.
  7. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease.
  8. Subject has had overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding).
  9. Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:

    • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease.
    • >= 2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring).
    • One first-degree relative with CRC diagnosed before the age of 60.
    • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP).
    • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome").
    • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis.
  10. Subject has a family history of:

    • Familial adenomatous polyposis (also referred to as "FAP").
    • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome").
  11. Participation in any "interventional" clinical study within the previous 30 days in which an experimental treatment is administered or might be administered through a randomized assignment of the subject to one or more study groups.
Both
50 Years to 84 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01397747
Exact Sciences 2011-01
No
Exact Sciences Corporation
Exact Sciences Corporation
Not Provided
Principal Investigator: Thomas Imperiale, MD Principal Study Investigator
Exact Sciences Corporation
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP